RCM
CYT

RA Capital Management’s Cyteir Therapeutics, Inc. Common Stock CYT Stock Holding History

RA Capital Management’s Portfolio CYT Stock Details CYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-3,350,506
Closed -$12.6M – 105
2022
Q1 		$12.6M Hold
3,350,506
– – 0.28% 70
2021
Q4 		$38.1M Hold
3,350,506
– – 0.67% 44
2021
Q3 		$58.8M Buy
3,350,506
+103,389
+3% +$1.93M 0.81% 38
2021
Q2 		$69.5M Buy
+3,247,117
New +$60.8M 1.12% 27

Other funds holding CYT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
OMC
OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RA Capital Management's CYT Position: Q2 2022 in Review

RA Capital Management sold out of Cyteir Therapeutics, Inc. Common Stock (CYT) in Q2 2022, closing a stake of 3,350,506 shares — an estimated $12.6M sold.

RA Capital Management first reported a position in CYT in Q2 2021 and held it in 4 quarters. The position peaked at $69.5M in Q2 2021. 45 funds tracked by Wall St. Rank hold CYT as of Q2 2022.

  • RA Capital Management reported no remaining Cyteir Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • RA Capital Management sold 3,350,506 Cyteir Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $12.6M.
  • RA Capital Management first reported a position in Cyteir Therapeutics, Inc. Common Stock in Q2 2021 and held it in 4 quarters.
  • RA Capital Management's Cyteir Therapeutics, Inc. Common Stock position peaked at $69.5M in Q2 2021.
  • 45 funds tracked by Wall St. Rank held Cyteir Therapeutics, Inc. Common Stock as of Q2 2022.

Based on RA Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.